According to filings with the U.S. Securities and Exchange Commission, Signos has raised $20 Million in new Series Unknown funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the current round of funding include: GV (Google Ventures), Dexcom, and Blue Cross Blue Shield of Alabama.

About Signos
Signos is a health technology company focused on helping people improve their metabolic health and manage weight through real-time insights from continuous glucose monitoring. Through its platform and educational content, such as the Signos 101 resources, the company guides users in understanding their continuous glucose monitor (CGM) data and experimenting with changes to diet, activity, and lifestyle to positively impact metabolic health. Signos emphasizes using personalized, data-driven feedback to help individuals make strategic adjustments that can lead to healthier habits and improved outcomes over time. By combining CGM data with practical guidance, the company positions itself as a partner for users looking to better understand how their daily choices affect their bodies. Overall, Signos aims to empower people with accessible tools and knowledge so they can take a more active, informed role in managing their health.

To learn more, visit https://www.signos.com/
Linkedin: https://www.linkedin.com/company/signoshealth/

Contact:
Sharam Fouladgar-Mercer, Chief Executive Officer
https://www.linkedin.com/in/sharamfm/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.